Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

SC to govt: Why can't SMA med be as cheap in India as in Pakistan, China? The Supreme Court of India seeks responses from the Centre and Roche on making the spinal muscular atrophy treatment drug ...

The AICPA endorsed four of the six bills, all of which passed with bipartisan support and were forwarded to the Senate.